1. Home
  2. ACN vs AMGN Comparison

ACN vs AMGN Comparison

Compare ACN & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accenture plc (Ireland)

ACN

Accenture plc (Ireland)

HOLD

Current Price

$287.97

Market Cap

167.6B

ML Signal

HOLD

Logo Amgen Inc.

AMGN

Amgen Inc.

HOLD

Current Price

$329.77

Market Cap

181.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACN
AMGN
Founded
1989
1980
Country
Ireland
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
167.6B
181.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ACN
AMGN
Price
$287.97
$329.77
Analyst Decision
Buy
Hold
Analyst Count
22
14
Target Price
$301.41
$321.69
AVG Volume (30 Days)
4.0M
2.7M
Earning Date
12-18-2025
02-03-2026
Dividend Yield
2.26%
3.06%
EPS Growth
1.33
65.12
EPS
12.09
12.93
Revenue
$70,725,557,000.00
$35,971,000,000.00
Revenue This Year
$7.07
$10.82
Revenue Next Year
$5.39
$1.73
P/E Ratio
$23.87
$25.43
Revenue Growth
6.58
10.56
52 Week Low
$229.40
$261.43
52 Week High
$398.35
$346.38

Technical Indicators

Market Signals
Indicator
ACN
AMGN
Relative Strength Index (RSI) 66.25 52.06
Support Level $273.00 $319.79
Resistance Level $291.09 $343.05
Average True Range (ATR) 7.73 6.96
MACD 1.12 -0.29
Stochastic Oscillator 90.69 48.15

Price Performance

Historical Comparison
ACN
AMGN

About ACN Accenture plc (Ireland)

Accenture is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises around the world. Customers of Accenture come from a variety of sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. Accenture is the world's largest professional services company by headcount with around 800,000 employees in over 120 countries.

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Share on Social Networks: